IO Biotech Hosts Key Opinion Leaders Webinar Series
Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.
Part 1: A new way to kill tumors – Phase 3 trial IO102-IO103 in combination with anti-PD-1 in advanced melanoma
Thursday April 28and @ 12:30 p.m. ET
NEW YORK, April 22, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel immunomodulatory cancer therapies based on its T-win® technology platform, announced today that she was going to be hosting a series of Key Opinion Leaders (KOL) webinars. Part 1, titled “A new way to kill tumors ― IO102-IO103 in combination with anti-PD-1 in advanced melanoma” will take place on Thursday, April 28, 2022 at 12:30 p.m. Eastern Time.
The webinar will include presentations from:
- Alexander Eggermont, MD, PhD (University Medical Center Utrecht, Comprehensive Cancer Center Munich)
- Jason J. Luke, MD, FACP (University of Pittsburgh and UPMC Hillman Cancer Center)
The discussion will include:
- The Current Therapeutic Landscape and Unmet Medical Needs in the Treatment of Patients with Metastatic Melanoma
- IO Biotech’s investigational immunotherapeutic vaccines, IO102-IO103, targeting IDO and PD-L1 expressing cells respectively
- The data behind the FDA’s decision to grant Breakthrough Therapy status based on the Phase 1/2 clinical trial MM1636 with 30 patients with metastatic melanoma receiving IO102-IO103 and anti-PD- 1
A live question and answer session will follow the official presentation. To register for the event, please click here.
About KOLsProfessor Alexander MM Eggermont, MD, PhD is an internationally recognized expert in surgical oncology, immunotherapy, melanoma, sarcoma and cancer drug development. He currently holds the positions of Scientific Director at Princess Máxima Center for Pediatric Oncology and Professor of Immunotherapy at University Medical Center Utrecht, The Netherlands; Professor of Oncology (Exceptional Class) at the University of Paris-Saclay, France; Coordinator, Comprehensive Cancer Center Program for Deutsche KrebsHilfe; and strategic advisor to the German Cancer Consortium (DKFZ).
Professor Eggermont was previously Director General of the Gustave Roussy Comprehensive Cancer Center, Villejuif, France (2010-2019) and Professor of Oncology (exceptional class) at the University of Paris-Saclay (2012-2020), France; Professor of Surgical Oncology (2003-2016) and Professor with International Networking in Cancer Research (2011-2018) at Erasmus University MC, Rotterdam, The Netherlands. He holds a PhD in Tumor Immunology from Erasmus University and is a Fellow of the National Cancer Institute of the National Institutes of Health (NIH-NCI, Stever Rosenberg Lab, Surgery Branch)).
Professor Eggermont has served as President of ECCO, President of EORTC, was a member of the ASCO Board of Trustees, served on the Editorial Board of the Journal of Clinical Oncology and is currently Editor-in-Chief of the European Journal of cancer. Professor Eggermont has published over 1000 peer-reviewed articles and his expertise has been recognized by numerous professional awards throughout his career.
Jason J. Luke, MD, FACP is an Associate Professor of Medicine at the University of Pittsburgh and UPMC’s Hillman Cancer Center, where he is Director of the Center for Immunotherapy and Drug Development. Dr. Luke specializes in the development of early-stage drugs for solid tumors (particularly novel immunotherapeutics and biomarkers of immunotherapeutic activity) as well as the management of cutaneous oncology, particularly melanoma patients.
Dr. Luke has been an international principal investigator on clinical trials of immunotherapies including but not limited to anti-PD1/L1, CTLA4, multiple secondary checkpoints, bispecific approaches (checkpoint, CD3 and cytokine), metabolic modifiers (IDO, A2Ar/CD73/CD39 and arginase), innate agonists of STING, TLRs and oncolytic viruses as well as cell therapies for solid tumors (TCR and CART). Dr. Luke has been a major contributor to the study of radiation and the microbiome in relation to cancer immunotherapy. Dr. Luke’s primary translational research focus is leveraging large-scale computing to advance cancer immunotherapy. Dr. Luke received his MD from Rosalind Franklin University of Medicine and Science in Chicago. He then pursued an internship and residency at Boston University Medical Center, followed by fellowships in medicine and medical oncology at Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center in New York. After his fellowship, Dr. Luke served as a tenure-track Type 1 Medicine Instructor at Harvard Medical School as well as a staff physician at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston. Subsequently, Dr. Luke served as an assistant professor at the University of Chicago. Dr. Luke is currently Editor-in-Chief of Clinical Cancer Research, Associate Editor of the Journal for Immunotherapy of Cancer, and Skin Cancer Section Editor for the American Cancer Society’s journal Cancer. Dr. Luke is actively involved in several professional societies, including the Society for Melanoma Research, Society for Immunotherapy of Cancer, American Association for Cancer Research, and American Society for Clinical Oncology (ASCO), having served on program committees scientist of each. Dr. Luke has received several awards for research and clinical care, including the Melanoma Research Foundation Humanitarian Award, Crain’s 40 under 40, Department of Defense (DOD) Career Development Award, Paul Calabresi Career Development in Clinical Oncology Award (K12), ASCO Merit Award as well as Young Investigator Awards from ASCO’s Melanoma Research Alliance, Cancer Research Foundation, and Conquer Cancer Foundation. Dr. Luke’s research has been supported by the National Institutes of Health, DOD, ASCO, National Comprehensive Cancer Network, and several industry and private foundations.
About IO Biotech IO Biotech is a clinical-stage biopharmaceutical company developing novel immunomodulatory cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate natural T cells to target immunosuppressive mechanisms. IO Biotech is advancing its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, through clinical studies and through clinical and preclinical development its other pipeline candidates. IO Biotech is headquartered in Copenhagen, Denmark, with additional offices in the United States (New York, New York and Rockville, Maryland) and the United Kingdom (Monmouthshire).
For more information, please visit www.iobiotech.com
Forward-looking statementThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the results and plans of ongoing and future clinical trials, are based on IO Biotech’s current assumptions and expectations regarding future events and trends, which affect or may affect its business, strategy, its operations or financial performance, and the actual results. and other events may differ materially from those expressed or implied by such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be relied upon unduly. Except to the extent required by law, IO Biotech assumes no obligation to update these statements, whether as a result of new information, future developments or otherwise.
Company Contact:Mai-Britt Zocca, Ph.D. President and CEO IO Biotech, Inc.firstname.lastname@example.org
Keith Vendola, MDCFOIO Biotech, Inc.email@example.com
Investor requests:Corey Davis, Ph.D. LifeSci Advisors212firstname.lastname@example.org
Media Contact:Raena Mina, Ph.D. LifeSci Communications email@example.com
Source: IO Biotech